Format

Send to

Choose Destination
Semin Cancer Biol. 2019 Dec 19. pii: S1044-579X(19)30398-0. doi: 10.1016/j.semcancer.2019.12.002. [Epub ahead of print]

Mechanisms of resistance to CAR T cell therapies.

Author information

1
Division of Oncology, Section of Stem Cell Biology, Washington University School of Medicine, St. Louis, MO, 63105, United States.
2
Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, United States.
3
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States.
4
Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States.
5
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States. Electronic address: mej@pennmedicine.upenn.edu.

Abstract

Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable success in the treatment of B cell malignancies. FDA approval of these therapies represents a watershed moment in the development of therapies for cancer. Despite the successes of the last decade, many patients will unfortunately not experience durable responses to CAR therapy. Emerging research has shed light on the biology responsible for these failures, and further highlighted the hurdles to broader success. Here, we review the recent research identifying how interactions between cancer cells and engineered immune cells result in resistance to CAR therapies.

KEYWORDS:

Chimeric antigen receptor; Resistance

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center